Using data from two clinical trials, we assessed the association of patients’ biological sex and age on CD4+ T cell and antibody responses to a mixture of 6 melanoma helper peptides presented by Class II HLA-DR molecules (6MHP) and on CD8+ T cell responses when vaccinating with 12 class I MHC-restricted melanoma peptides (12MP) plus either 6MHP or a tetanus helper T cell peptide (Tet). This evidence concerns the gene CD8A and melanoma.